Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Mevalotin Useful Against CAD in Elderly Women
April 7, 2008
- Surveys Show Increasing Interest in Generics
April 7, 2008
- Self-Injection at Home a Boon to Patients with Migraines
April 7, 2008
- Aiming at Eliminating "Drug Lag": New PMDA Chief Executive
April 7, 2008
- Long QT Risk Can Be Assessed Using Proarrhythmia Model
April 7, 2008
- Chuikyo Approves NHI Prices for 21 Products (14 APIs)
April 7, 2008
- Toyama Chemical to Review Licensing Policy
April 7, 2008
- TOPICS／Pfizer Starts Publicity Campaign on Growth Disorders in Girls
April 7, 2008
- 11 New Drugs to Be Officially Approved in April
April 7, 2008
- REGULATORY NEWS IN BRIEF
April 7, 2008
- Collaborative Multinational Clinical Trials Increasingly Diversified
April 7, 2008
- Japanese Patients Account for Nearly 50% of Total in Asian Studies
April 7, 2008
- PMDA Set No Minimum Number of Japanese Patients Required in Multinational Trials: Mr Mori
April 7, 2008
- Isao Teshirogi Appointed Shionogi President
April 7, 2008
- PMDA to Enhance Cooperation with Authorities in Other East Asian Countries: Mr Mori
April 7, 2008
- SELF-MEDICATION NEWS IN BRIEF
April 7, 2008
- Notices Received for 35 Collaborative Multinational Trials: Mr Mori
April 7, 2008
- Serious Effort Needed to Bring about Improvements : FJPWA President Matsutani
April 7, 2008
- Takeda Discontinues Development of TAK-475
April 7, 2008
- BUSINESS NEWS IN BRIEF
April 7, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…